Chronic Myelomonocytic Leukemia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic myelomonocytic leukemia. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
6
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Chronic Myelomonocytic Leukemia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic myelomonocytic leukemia. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
29
2
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vidaza
azacitidine
 Bristol-Myers Squibb 6 73 — 2029-05-14

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12053482 Vidaza method of use 88 2029-05-14
12053482 Vidaza method of use 88 2029-05-14
8846628 Vidaza method of use 68 2030-06-03
8846628 Vidaza method of use 68 2030-06-03
11571436 Vidaza formulation 63 2029-05-14
11571436 Vidaza formulation 63 2029-05-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11571436 Vidaza formulation 63 2029-05-14
11571436 Vidaza formulation 63 2029-05-14
8846628 Vidaza method of use 68 2030-06-03
8846628 Vidaza method of use 68 2030-06-03
12053482 Vidaza method of use 88 2029-05-14
12053482 Vidaza method of use 88 2029-05-14

Related